Search
vutrisiran (Amvuttra)
Indications:
- treatment of polyneuropathy of hereditary transthyretin amyloidosis in adults
Dosage:
- 25 mg SQ every 3 months
0.5 mL vutrisiran 50 mm/mL Prefilled Syringe
Adverse effects:
- reduced vitamin A*
- arthralgia
- dyspnea
* supplement with the recommended daily allowance of vitamin A
Mechanism of action:
- transthyretin-directed small interfering RNA
General
neurologic agent
short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)
References
- Highlights of Prescribing Information
https://www.alnylam.com/sites/default/files/pdfs/amvuttra-us-prescribing-information.pdf